Articles tagged with Sars Cov 2
Researchers at Hokkaido University identified 2-thiouridine as a broad-spectrum antiviral drug candidate targeting ssRNA+ viruses. It inhibits viral replication and increases survival rates in mice models for dengue and COVID-19.
Researchers identified enhanced B-cell and T-cell responses in fully vaccinated individuals who became infected with SARS-CoV-2, generating immunological memory to prevent severe infection. Vaccine-primed memory T cells play a critical role in preventing severe COVID-19.
A review in the Journal of Neurochemistry suggests a link between COVID-19 and Alzheimer's disease, with age being the largest contributing factor. Emerging evidence may further support this association, with research assessing influences on AD neuropathology.
A study published in the Journal of Internal Medicine found that SARS-CoV-2 infection may worsen lower urinary tract symptoms in men. The research involved 17,986 men with medication for LUTS, half of whom had COVID-19, and showed a significant increase in urine retention, UTIs, and enlarged prostate issues.
Researchers will study the spread of SARS-CoV-2 among deer, including captive and wild populations, as well as its relationship with humans and the environment. The project aims to understand disease ecology in whole systems and inform better management practices for deer producers.
A primary mRNA vaccine series offers significant protection against SARS-CoV-2 infection in Singaporean children aged 1-4. The study found a low incidence of hospitalization and severe illness, but highlights the potential benefits of vaccination in preventing infection and sequelae.
Research found that young children's immune systems produce protective antibodies at high levels for up to 300 days after infection. Unlike adults, children have high levels of inflammatory cytokines in their noses but not in their blood, potentially explaining the mildness of COVID-19 in this age group.
Scientists have discovered the open and closed states of the coronavirus E ion channel, which could help develop antiviral drugs to reduce inflammation. The study's findings provide insights into the channel's structure and function, allowing researchers to design molecules that can bind to it and prevent inflammation.
A new AI tool named EVEscape can predict future viral variants of concern, potentially helping scientists develop more effective vaccines and therapies. The tool uses evolutionary and biological information to forecast which mutations will occur in viruses like SARS-CoV-2.
A new study reveals that immunity to SARS-CoV-2 variants depends on previous exposure and vaccination history. The research found significant differences in immune responses to various variants, highlighting the need for personalized vaccine approaches.
Post-Acute Sequelae of COVID-19 research aims to track long-term health symptoms in survivors. A $3.7 million grant will support the development of self-supervised deep learning technologies to recognize post-COVID lung progression phenotypes.
A portable laboratory device can rapidly detect SARS-CoV-2 RNA from environmental surfaces, holding promise for scenarios where access to testing labs is challenging. The device uses a compact centrifuge and PCR technology to provide highly sensitive on-site detection.
Researchers have developed a synthetic peptide that could help reduce vascular problems associated with acute respiratory distress syndrome in COVID-19. The peptide, called TIP, works by binding to a subunit of the epithelial sodium channel, which helps maintain barrier function and prevent damage from viral proteins.
Scientists have developed a trivalent vaccine candidate that provides broad and long-lasting protection against COVID-19 infection by delivering the vaccine via the nose. The vaccine triggers a strong neutralizing antibody response and protects mucosal areas, preventing disease symptoms.
Using data from Mass General Brigham’s electronic health records, researchers found that SARS-CoV-2 accounted for approximately 1 in 6 cases of sepsis during the COVID-19 pandemic. The mortality rate for patients with SARS-CoV-2-associated sepsis was initially high but declined over time.
A recent study published in JAMA Network Open reveals that viral pathogens, particularly SARS-CoV-2, are a significant contributor to sepsis. The researchers found that approximately 1 in 6 cases of sepsis were associated with SARS-CoV-2 infections during the COVID-19 pandemic.
A new study reveals that COVID-19 triggers a dangerous immune response in hardened fatty deposits lining the heart's largest blood vessels. This inflammation can lead to immediate and longer-lasting heart issues, including plaque rupture and blockage of blood flow.
Researchers at the University of Surrey have developed an electronic diagnostic test for bacteria and viruses, including SARS-CoV-2. The 'Electro-chemical LAMP' (eLAMP) test is affordable, sensitive, and can be performed at home or in a hospital lab.
Researchers identified two SARS-CoV-2 protein mutations linked to severe COVID-19 symptoms and increased inflammation. The mutations, known as KR, were found in patients with higher viral loads and more severe symptoms.
University of Liverpool researchers develop a new material that captures coronavirus particles with minimal impact on breathability, increasing efficiency by approximately 93%. The new material has the potential to be used in various applications, including face masks and air filters.
A new vaccine candidate has shown protection against a range of coronaviruses, including current and future variants, by targeting the critical regions of the virus that it needs to complete its life cycle. The vaccine technology, developed at the University of Cambridge, aims to provide broad-based protection against emerging viruses.
Researchers identified specific blood biomarkers that can accurately identify patients with long COVID, revealing distinct immune and hormone function differences. The study also found abnormal T cell activity, reactivation of latent viruses, and reduced cortisol levels in patients with long COVID.
A study using engineered mice found that BA.5, a contagious omicron subvariant, replicates rapidly early during infection, causing significant weight loss and high levels of inflammatory cells and cytokines in lungs.
Researchers have found a link between the antiviral drug molnupiravir and a pattern of mutations in the SARS-CoV-2 virus. The study used global sequencing databases to map mutations over time, identifying a mutational signature associated with individuals who took molnupiravir.
A new study has found that bats' extraordinary ability to host and survive infections may be linked to their low cancer rates. Researchers sequenced the genomes of two bat species and compared them to other mammals, discovering genetic adaptations that allow bats to tolerate viral infections.
A nationwide study found that early treatment with plasma from recovered COVID patients can reduce the risk of developing post-COVID conditions. The research also suggests that elevated cytokine levels, particularly interleukin-6, may contribute to long COVID symptoms.
Researchers identified a link between SARS-CoV-2 infection and Alzheimer's disease-like cognitive symptoms, triggered by Tau protein hyperphosphorylation. The study found increased Tau levels in infected cells, indicating pathological alterations to the protein.
The American College of Physicians has issued updated rapid, living practice points on treating COVID-19 patients in outpatient settings. The new guidance supports the use of molnupiravir or nirmatrelvir-ritonavir for symptomatic patients with confirmed mild to moderate COVID-19.
Receiving two doses of BNT162b2 vaccine was associated with lower risk of COVID-19 emergency department and outpatient visits. The risk appeared lower for those with two versus three doses, despite Omicron sublineages becoming dominant.
A new SARS-CoV-2 variant Eris has been detected, showing an advantage in evading neutralizing antibodies and increasing infectivity. The study found that Eris is less effectively neutralized by antibodies present in the blood of vaccinated individuals or those with a previous infection.
A team of researchers led by Penn State aims to test 58 wildlife species for SARS-CoV-2 using a $4.5M USDA grant. The goal is to monitor potential spillback to humans and understand cross-species transmission, which poses a risk to human health and agricultural systems.
Researchers have developed a new vaccination method that induces the production of antibodies in mucus, which can disable viruses. This approach has shown promising results in monkeys, suggesting that oral vaccines against SARS-CoV-2 may be more effective and popular than traditional subcutaneous vaccinations.
The Mount Sinai Hospital received a $13 million NIH grant to create vaccines that can protect against various types of coronaviruses. The project aims to develop variant-proof, universal vaccines that offer broad protection against existing and future SARS-CoV-2 variants, pandemic, zoonotic, and seasonal coronaviruses.
A new editorial paper explores the effectiveness of the third dose booster vaccine against SARS-CoV-2 in immunocompromised individuals. Researchers found that while the vaccine improves vaccine effectiveness across various measures, its benefits are not as significant for patients with cancer.
Researchers at UTSA are studying the bioactive properties of Sweet Annie, a plant used in traditional Chinese medicine for over 2,000 years. The study reveals that arteannuin B from the plant has anti-COVID and anti-glioblastoma properties, offering new avenues for targeted therapy.
A study published in Nature has identified 51 significant genome-wide loci associated with COVID-19 severity and SARS-CoV-2 susceptibility. The research adds 28 new loci to the list, providing valuable information about three key biological pathways involved in determining disease outcomes.
Researchers from Trinity College Dublin have made significant discoveries on how lung cells respond to influenza viruses, identifying two key molecular pathways that trigger the release of cytokines and cell death. These findings hold promise for treating people affected by such viruses.
Patients with cancer had disparate COVID-19 mortality rates during the winter Omicron wave compared to the general US population. The study suggests that immune-evasive SARS-CoV-2 variants pose a significant threat, requiring prioritized efforts to prevent transmission.
A study of 11.7 million adults in Ontario, Canada, reveals that COVID-19 infection is associated with significantly higher mortality rates among cancer patients who do not receive prioritized critical care treatment.
New SARS-CoV-2 variants, such as BQ.11 and XBB.1.5, bind to cells more tightly and evade antibodies more efficiently than earlier variants, allowing reinfections and breakthrough infections. Previous infection or vaccination can generate antibodies that recognize some proteins on newer variants, reducing the risk of serious illness.
Researchers at Affilogic developed nanofitins that inhibit SARS-CoV-2 by binding to its spike proteins, demonstrating quick reach and clearance of the lungs. The technology has potential for treating other infectious respiratory diseases with lower costs and higher accessibility.
Researchers found that white-tailed deer are virus reservoirs, promoting ongoing mutation of the SARS-CoV-2 virus. At least 30 infections were introduced by humans, and an estimated 23.5% of deer had been infected at one time or another.
Patients with severe long COVID often struggle with fatigue and exertion intolerance, with recovery rates varying depending on the initial infection's severity. A recent study found that those with ME/CFS experience little to no improvement in symptoms, while some patients in a second group show gradual improvement over time.
This study found a correlation between hospital-onset SARS-CoV-2 infections and community-onset infections, highlighting the importance of ongoing surveillance and prevention measures. The findings suggest that hospitals should be particularly vigilant when community incidence rates are high, in order to reduce in-hospital transmission.
Researchers have identified a key protein in SARS-CoV-2 that, when targeted, elicits a robust immune response. A live-attenuated vaccine based on this protein shows promise in preventing disease and offering long-lasting immunity. The approach could target areas of the genome less likely to change with variants.
HSE biologists explain how coronavirus evolves from Wuhan variant to Omicron, highlighting the crucial role of microRNA molecules in the process. The study found that substitutions in the viral genome disrupted microRNA binding regions, leading to the emergence of more contagious and resilient strains.
Researchers investigated SARS-CoV-2 responses in 222 donors from Central Africa, Europe and East Asia. They found disparities in immune responses due to blood cell composition, latent cytomegalovirus infection and human genetic factors. These population differences may help improve patient management in future epidemics.
SARS-CoV-2's nucleocapsid protein (N) uses human body temperature to replicate, binding to RNA motifs at specific spatial folds. The study reveals new functions and potential targets for antiviral drugs.
A recent study published in JAMA Pediatrics analyzed the severity of COVID-19 in pediatric patients, finding that intensive care unit admissions decreased over time but ventilatory support remained stable in younger children under age 5.
A long-term study of nearly 2,400 solid organ transplant recipients found that COVID-19 vaccination significantly reduced hospitalization rates, with a 75% decrease in later omicron waves. Despite this, post-vaccination SARS-CoV-2 viral infections remain common, highlighting the importance of vaccination in high-risk populations.
Researchers have found that a prostate cancer drug called proxalutamide can block SARS-CoV-2 viral entry and reduce inflammation. The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.
A NIH-funded study found that severe COVID-19 can cause lasting changes in the innate immune system, boosting inflammatory cytokine production and leading to chronic inflammation. Early treatment with IL-6 inhibitors may help mitigate these effects.
A new study found that individuals exposed to common cold-causing coronaviruses have immune responses that may protect them from future SARS-CoV-2 infections. Researchers hope this insight will inform global infectious disease outbreak preparedness and vaccine development.
Researchers at Martin-Luther-Universität Halle-Wittenberg have developed a new method for detecting SARS-CoV-2 using MALDI-TOF mass spectrometry, which takes just two hours from swab to result. The approach can also detect other pathogens and is more flexible than existing PCR tests.
Scientists have discovered that SARS-CoV-2 can infect cells using multiple entry points beyond ACE2, explaining its ability to jump between species. This finding highlights the need for continued monitoring of coronaviruses and their potential to cause future pandemics.
A panel of genetically diverse mice has been created to accurately model the variable human response to SARS-CoV-2 infection. The mice exhibit different levels of disease severity, ranging from asymptomatic to lethal, and can help scientists discover biomarkers of disease severity and evaluate countermeasures.
Researchers found that molnupiravir efficiently blocked SARS-CoV-2 transmission when administered at a human effect size-equivalent dose, but paxlovid did not. The study used ferret animal models and found that molnupiravir completely suppressed transmission at all tested doses.
A large study found that fully vaccinated individuals have lower concentrations of inflammatory markers than unvaccinated participants after symptomatic COVID-19 infection. This suggests that vaccination significantly reduces morbidity and mortality by reducing elevated levels of cytokines and chemokines.
A new adjuvanted intranasal vaccine has shown promise in protecting both young and old mice against SARS-CoV-2 infection. The vaccine combines an RNA-based molecule with a nanoemulsion, resulting in a strong immune response.
A recent study of Massachusetts schools found low secondary attack rates for SARS-CoV-2 among school-based contacts. The study highlights the importance of ongoing surveillance efforts to maintain optimal disease prevention strategies.